Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

5-APDB

5-APDB molecule structure5-APDB molecule structure
This article is a stubmissing:
Subjective Effects
Interactions
Tolerance
Legality
Chemical Class
Benzofuran

5-APDB is a benzofuran-class entactogen and amphetamine stimulant with structure and effects similar to MDMA. It is an analogue of MDA in which a heterocyclic oxygen is replaced by a methylene bridge1. A team led by David E. Nichols at Purdue University investigated entactogen structure-activity relationships to determine whether potentially useful psychopharmacological properties could be dissociated from serotonergic neurotoxic effects1, and it was described in a 1993 Journal of Medicinal Chemistry paper1.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~50 mg
Light50-75 mg
Moderate75-125 mg
Heavy125-200 mg

Duration

Onset20-60 minutes
Total4-8 hours

Subjective Effects

Subjective Effects not written up yet

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → brown2
Mecke(ME)
white → brown2
Mandelin(MD)
yellow2 → brown2
Robadope(RB)
orange1 → pink1 → pink1 → pink2 → purple2
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

5-APDB acts primarily as a highly selective serotonin releasing agent. It also weakly inhibits serotonin reuptake and inhibits dopamine and norepinephrine reuptake, with additional activity at serotonin receptors.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Low

Classified as habit-forming. As an entactogenic stimulant with serotonin-releasing properties similar to MDMA, some potential for psychological habituation exists.

Psychosis Risk

Visual and auditory hallucinations have been reported as negative effects.

History & Culture

5-APDB was developed by a team led by David E. Nichols at Purdue University as part of research into non-neurotoxic MDMA analogues and was first described in 1993. Nichols and colleagues described 5-APDB and 6-APDB as MDMA analogues in that year.…

Legality

Legality not written up yet

References

Citations

  1. Synthesis and Pharmacological Examination of Benzofuran, Indan, and Tetralin Analogues of 3,4-(Methylenedioxy)amphetamine. Journal of Medicinal Chemistry (1993). https://chemistry.mdma.ch/hiveboard/rhodium/pdf/nichols/nichols-benzofuran.indan.tetralin.mda-analogs.pdf123

Further Reading

  1. Hill et al. 2023 - Locomotor and discriminative stimulus effects of three benzofuran compounds in comparison to abused psychostimulants

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 5-APDB article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.